SPK 1001
Alternative Names: SPK-1001Latest Information Update: 28 Mar 2023
Price :
$50 *
At a glance
- Originator University of Iowa Research Foundation
- Developer Spark Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neuronal ceroid lipofuscinosis
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for preclinical development in Neuronal ceroid lipofuscinosis in USA (Parenteral)
- 10 Mar 2021 Preclinical development for Neuronal ceroid lipofuscinosis is still ongoing in USA (Spark Therapeutics pipeline, March 2021)